Difference between revisions of "Mark McClellan"
m (Text replacement - "|twitter= " to "") |
(unstub) |
||
Line 3: | Line 3: | ||
|amazon= | |amazon= | ||
|image=Mark McClellan.jpg | |image=Mark McClellan.jpg | ||
− | |nationality= | + | |nationality=US |
− | |birth_date=1963 | + | |birth_date=June 26, 1963 |
|birth_place=Austin, Texas, U.S. | |birth_place=Austin, Texas, U.S. | ||
|death_date= | |death_date= | ||
|death_place= | |death_place= | ||
− | |constitutes= | + | |description=Food and Drug Administration Commissioner who "streamlined" regulatory requirements for new drugs. Later made big bucks on boards of [[Big Pharma]] companies. |
+ | |constitutes=Big Pharma/Lobbyist,health bureaucrat | ||
+ | |parents=Carole Keeton Strayhorn,Barr McClellan | ||
+ | |siblings=Scott McClellan | ||
|historycommons=http://www.historycommons.org/entity.jsp?entity=mark_mcclellan_1 | |historycommons=http://www.historycommons.org/entity.jsp?entity=mark_mcclellan_1 | ||
|sourcewatch=http://www.sourcewatch.org/index.php/Mark_McClellan | |sourcewatch=http://www.sourcewatch.org/index.php/Mark_McClellan | ||
− | |alma_mater=University of Texas | + | |alma_mater=University of Texas at Austin, Harvard University, Massachusetts Institute of Technology |
|political_parties=Republican | |political_parties=Republican | ||
|employment={{job | |employment={{job | ||
Line 17: | Line 20: | ||
|start=March 25, 2004 | |start=March 25, 2004 | ||
|end=October 14, 2006 | |end=October 14, 2006 | ||
+ | |appointer=George W. Bush | ||
}}{{job | }}{{job | ||
|title=Commissioner of Food and Drugs | |title=Commissioner of Food and Drugs | ||
Line 22: | Line 26: | ||
|end=March 25, 2004 | |end=March 25, 2004 | ||
|next=18 July 2005 | |next=18 July 2005 | ||
+ | |appointer=George W. Bush | ||
+ | |description="Streamlined" regulatory requirements for new drugs. | ||
}} | }} | ||
}} | }} | ||
+ | '''Mark Barr McClellan''' was commissioner of the United States Food and Drug Administration under President [[George W. Bush]] from 2002 through 2004, and subsequently as administrator of the [[Centers for Medicare and Medicaid Services]] from 2004 through 2006.<ref>https://www.nytimes.com/2006/09/08/opinion/08fri3.html</ref><ref>https://query.nytimes.com/gst/fullpage.html?res=9907E3D71F3BF936A2575AC0A9659C8B63</ref><ref>https://query.nytimes.com/gst/fullpage.html?res=990DEFDC1E3DF932A15751C0A9629C8B63</ref> He was part of 2021 the [[Covid Commission Planning Group]] under [[Philip Zelikow]]. | ||
+ | |||
+ | ==Food and Drug Administration Commissioner== | ||
+ | When Mark McClellan was named US Food and Drug Administration Commissioner, he was quickly confirmed by both political parties. In his first major speech to the "[[healthcare]]" industry in January 2003, McClellan set the tone for his tenure, stating, "Along with the new health policy initiatives in Congress, we need a lower-cost process for regulating new medical technologies — less costly, more rapid, and more predictable ways of determining that new drugs and other treatments meet [[FDA]]'s high standards of safety and effectiveness." He stated he intended "streamlining regulatory requirements, clarifying guidance to industry, and meeting with companies early and often in the drug-approval process".<ref>https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14063-9.pdf</ref> | ||
+ | |||
+ | ==Revolving door== | ||
+ | In 2007, he was appointed as the chair of the [[Reagan-Udall Foundation]], a [[public-private partnership|public-private "partnership"]] between the U.S. Food and Drug Administration and [[Big Pharma]].<ref>https://reaganudall.org/about-us/board-directors</ref> | ||
+ | |||
+ | In 2013, Mark McClellan was given a position on the board of pharmaceutical giant [[Johnson & Johnson]]. In 2018, McClellan received $285,000 for sitting there, and had since taking the post been given $1 million in cash and stock awards.<ref name=kff/> | ||
+ | |||
+ | McClellan also receives compensation as a member of the advisory board of privately held [[Alignment Healthcare]], which employs [[doctors]] and provides chronic-care management for [[Medicare Advantage]] plans in three states. Alignment Healthcare declined to disclose his compensation.<ref name=kff>https://kffhealthnews.org/news/health-policy-expert-and-former-fda-chief-mark-mcclellans-ties-to-pharma-draw-scrutiny/</ref> | ||
+ | |||
+ | He was appointed to Big Pharma corporation [[Cigna]]'s board of directors in July 2018<ref>https://www.raps.org/News-and-Articles/News-Articles/2018/9/Revolving-Door-Between-Industry-and-FDA-Continues</ref>. In 2019, [[life sciences]] and [[health data]] company [[Seer]] told that it had lured Mark McClellan on to its board. "Mark’s deep understanding of the [[health care|health care ecosystem]] and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market," said Seer chief and founder [[Omid Farokhzad]] in a statement.<ref>https://endpts.com/seer-entices-ex-fda-commissioner-mcclellan-to-its-board-vanda-tests-tradipitant-in-motion-sickness-study/</ref> | ||
+ | |||
+ | He also had a position as Senior Fellow in Economic Studies at [[Brookings Institution]] from [[2007]]<ref>https://www.brookings.edu/wp-content/uploads/2016/07/mcclellanm_cv.pdf</ref>. | ||
+ | |||
{{SMWDocs}} | {{SMWDocs}} | ||
==References== | ==References== | ||
{{reflist}} | {{reflist}} | ||
− |
Revision as of 03:10, 13 December 2023
Mark McClellan (Big Pharma/Lobbyist, health bureaucrat) | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Born | June 26, 1963 Austin, Texas, U.S. | ||||||||||||||||||||||||
Nationality | US | ||||||||||||||||||||||||
Alma mater | University of Texas at Austin, Harvard University, Massachusetts Institute of Technology | ||||||||||||||||||||||||
Parents | • Carole Keeton Strayhorn • Barr McClellan | ||||||||||||||||||||||||
Siblings | Scott McClellan | ||||||||||||||||||||||||
Member of | Covid Commission Planning Group | ||||||||||||||||||||||||
Party | Republican | ||||||||||||||||||||||||
Food and Drug Administration Commissioner who "streamlined" regulatory requirements for new drugs. Later made big bucks on boards of Big Pharma companies.
|
Mark Barr McClellan was commissioner of the United States Food and Drug Administration under President George W. Bush from 2002 through 2004, and subsequently as administrator of the Centers for Medicare and Medicaid Services from 2004 through 2006.[1][2][3] He was part of 2021 the Covid Commission Planning Group under Philip Zelikow.
Contents
Food and Drug Administration Commissioner
When Mark McClellan was named US Food and Drug Administration Commissioner, he was quickly confirmed by both political parties. In his first major speech to the "healthcare" industry in January 2003, McClellan set the tone for his tenure, stating, "Along with the new health policy initiatives in Congress, we need a lower-cost process for regulating new medical technologies — less costly, more rapid, and more predictable ways of determining that new drugs and other treatments meet FDA's high standards of safety and effectiveness." He stated he intended "streamlining regulatory requirements, clarifying guidance to industry, and meeting with companies early and often in the drug-approval process".[4]
Revolving door
In 2007, he was appointed as the chair of the Reagan-Udall Foundation, a public-private "partnership" between the U.S. Food and Drug Administration and Big Pharma.[5]
In 2013, Mark McClellan was given a position on the board of pharmaceutical giant Johnson & Johnson. In 2018, McClellan received $285,000 for sitting there, and had since taking the post been given $1 million in cash and stock awards.[6]
McClellan also receives compensation as a member of the advisory board of privately held Alignment Healthcare, which employs doctors and provides chronic-care management for Medicare Advantage plans in three states. Alignment Healthcare declined to disclose his compensation.[6]
He was appointed to Big Pharma corporation Cigna's board of directors in July 2018[7]. In 2019, life sciences and health data company Seer told that it had lured Mark McClellan on to its board. "Mark’s deep understanding of the health care ecosystem and visionary insights on policy reform will be crucial in informing our thinking as we work to bring our liquid biopsy and life sciences products to market," said Seer chief and founder Omid Farokhzad in a statement.[8]
He also had a position as Senior Fellow in Economic Studies at Brookings Institution from 2007[9].
Event Participated in
Event | Start | End | Location(s) | Description |
---|---|---|---|---|
WEF/Annual Meeting/2004 | 21 January 2004 | 25 January 2004 | Switzerland World Economic Forum | 2068 billionaires, CEOs and their politicians and "civil society" leaders met under the slogan Partnering for Prosperity and Security. "We have the people who matter," said World Economic Forum Co-Chief Executive Officer José María Figueres. |
References
- ↑ https://www.nytimes.com/2006/09/08/opinion/08fri3.html
- ↑ https://query.nytimes.com/gst/fullpage.html?res=9907E3D71F3BF936A2575AC0A9659C8B63
- ↑ https://query.nytimes.com/gst/fullpage.html?res=990DEFDC1E3DF932A15751C0A9629C8B63
- ↑ https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(03)14063-9.pdf
- ↑ https://reaganudall.org/about-us/board-directors
- ↑ a b https://kffhealthnews.org/news/health-policy-expert-and-former-fda-chief-mark-mcclellans-ties-to-pharma-draw-scrutiny/
- ↑ https://www.raps.org/News-and-Articles/News-Articles/2018/9/Revolving-Door-Between-Industry-and-FDA-Continues
- ↑ https://endpts.com/seer-entices-ex-fda-commissioner-mcclellan-to-its-board-vanda-tests-tradipitant-in-motion-sickness-study/
- ↑ https://www.brookings.edu/wp-content/uploads/2016/07/mcclellanm_cv.pdf